Blood product usage in patients without and with clinically serious pulmonary adverse events (CSPAE) and without and with acute lung injury
| Platelet components* . | ||||||
|---|---|---|---|---|---|---|
| Group . | Treatment . | N . | Mean (SD) . | Median . | Min, Max . | P† . |
| No CSPAE | Test | 263 | 7.3 (7.59) | 5.0 | 1.0, 46.0 | .0002 |
| Reference | 282 | 5.3 (6.26) | 3.0 | 1.0, 58.0 | ||
| CSPAE | Test | 55 | 17.8 (13.35) | 16.0 | 1.0, 55.0 | .3492 |
| Reference | 45 | 15.2 (12.44) | 11.0 | 1.0, 64.0 | ||
| No ALI | Test | 36 | 18.7 (13.92) | 16.0 | 1.0, 55.0 | .1595 |
| Reference | 29 | 14.6 (13.94) | 9.0 | 1.0, 64.0 | ||
| ALI | Test | 19 | 16.1 (12.39) | 12.0 | 2.0, 39.0 | .6073 |
| Reference | 16 | 16.3 (9.45) | 14.0 | 4.0, 36.0 | ||
| Platelet components* . | ||||||
|---|---|---|---|---|---|---|
| Group . | Treatment . | N . | Mean (SD) . | Median . | Min, Max . | P† . |
| No CSPAE | Test | 263 | 7.3 (7.59) | 5.0 | 1.0, 46.0 | .0002 |
| Reference | 282 | 5.3 (6.26) | 3.0 | 1.0, 58.0 | ||
| CSPAE | Test | 55 | 17.8 (13.35) | 16.0 | 1.0, 55.0 | .3492 |
| Reference | 45 | 15.2 (12.44) | 11.0 | 1.0, 64.0 | ||
| No ALI | Test | 36 | 18.7 (13.92) | 16.0 | 1.0, 55.0 | .1595 |
| Reference | 29 | 14.6 (13.94) | 9.0 | 1.0, 64.0 | ||
| ALI | Test | 19 | 16.1 (12.39) | 12.0 | 2.0, 39.0 | .6073 |
| Reference | 16 | 16.3 (9.45) | 14.0 | 4.0, 36.0 | ||
| Red cell components . | ||||||
|---|---|---|---|---|---|---|
| Group . | Treatment . | N . | Mean (SD) . | Median . | Min, Max . | P† . |
| No CSPAE | Test | 263 | 4.7 (4.13) | 4.0 | 0.0, 27.0 | .0140 |
| Reference | 282 | 4.0 (3.64) | 4.0 | 0.0, 34.0 | ||
| CSPAE | Test | 55 | 9.0 (5.07) | 8.0 | 0.0, 20.0 | .5848 |
| Reference | 45 | 10.4 (6.89) | 8.0 | 2.0, 31.0 | ||
| No ALI | Test | 36 | 8.8 (4.76) | 8.0 | 0.0, 20.0 | .9100 |
| Reference | 29 | 10.2 (7.59) | 8.0 | 2.0, 31.0 | ||
| ALI | Test | 19 | 9.4 (5.74) | 8.0 | 2.0, 20.0 | .5501 |
| Reference | 16 | 10.7 (5.61) | 9.5 | 3.0, 21.0 | ||
| Red cell components . | ||||||
|---|---|---|---|---|---|---|
| Group . | Treatment . | N . | Mean (SD) . | Median . | Min, Max . | P† . |
| No CSPAE | Test | 263 | 4.7 (4.13) | 4.0 | 0.0, 27.0 | .0140 |
| Reference | 282 | 4.0 (3.64) | 4.0 | 0.0, 34.0 | ||
| CSPAE | Test | 55 | 9.0 (5.07) | 8.0 | 0.0, 20.0 | .5848 |
| Reference | 45 | 10.4 (6.89) | 8.0 | 2.0, 31.0 | ||
| No ALI | Test | 36 | 8.8 (4.76) | 8.0 | 0.0, 20.0 | .9100 |
| Reference | 29 | 10.2 (7.59) | 8.0 | 2.0, 31.0 | ||
| ALI | Test | 19 | 9.4 (5.74) | 8.0 | 2.0, 20.0 | .5501 |
| Reference | 16 | 10.7 (5.61) | 9.5 | 3.0, 21.0 | ||
| Plasma components . | ||||||
|---|---|---|---|---|---|---|
| Group . | Treatment . | N . | Mean (SD) . | Median . | Min, Max . | P† . |
| No CSPAE | Test | 263 | 0.1 (0.57) | 0.0 | 0.0, 6.0 | .4851 |
| Reference | 282 | 0.1 (0.66) | 0.0 | 0.0, 8.0 | ||
| CSPAE | Test | 55 | 1.2 (3.15) | 0.0 | 0.0, 16.0 | .0871 |
| Reference | 45 | 4.8 (14.64) | 0.0 | 0.0, 72.0 | ||
| No ALI | Test | 36 | 0.3 (1.37) | 0.0 | 0.0, 8.0 | .0321 |
| Reference | 29 | 1.5 (3.49) | 0.0 | 0.0, 13.0 | ||
| ALI | Test | 19 | 2.9 (4.63) | 0.0 | 0.0, 16.0 | .6669 |
| Reference | 16 | 10.8 (23.39) | 0.0 | 0.0, 72.0 | ||
| Plasma components . | ||||||
|---|---|---|---|---|---|---|
| Group . | Treatment . | N . | Mean (SD) . | Median . | Min, Max . | P† . |
| No CSPAE | Test | 263 | 0.1 (0.57) | 0.0 | 0.0, 6.0 | .4851 |
| Reference | 282 | 0.1 (0.66) | 0.0 | 0.0, 8.0 | ||
| CSPAE | Test | 55 | 1.2 (3.15) | 0.0 | 0.0, 16.0 | .0871 |
| Reference | 45 | 4.8 (14.64) | 0.0 | 0.0, 72.0 | ||
| No ALI | Test | 36 | 0.3 (1.37) | 0.0 | 0.0, 8.0 | .0321 |
| Reference | 29 | 1.5 (3.49) | 0.0 | 0.0, 13.0 | ||
| ALI | Test | 19 | 2.9 (4.63) | 0.0 | 0.0, 16.0 | .6669 |
| Reference | 16 | 10.8 (23.39) | 0.0 | 0.0, 72.0 | ||